Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, May 24 '25)

Image
By G.M.

 


    Am J Med

  1. LIPPI G, Sanchis-Gomar F, Lavie CJ
    The recent (2018-2022) US monthly mortality for acute myocardial infarction still peaks in December and January.
    Am J Med. 2025 Jan 18:S0002-9343(25)00035-X. doi: 10.1016/j.amjmed.2025.
    PubMed         Abstract available

  2. STAHLBERG M, Fischer K, Tahhan M, Zhao A, et al
    Post-Acute COVID-19 Syndrome: Prevalence of Peripheral Microvascular Endothelial Dysfunction and Associations With NT-ProBNP Dynamics.
    Am J Med. 2025;138:1019-1028.
    PubMed         Abstract available

  3. ZHOU T, Sawano M, Arun AS, Caraballo C, et al
    Internal Tremors and Vibrations in Long COVID: A Cross-Sectional Study.
    Am J Med. 2025;138:1010-1018.
    PubMed         Abstract available

  4. SANAL-HAYES NEM, Mclaughlin M, Hayes LD, Berry ECJ, et al
    Examining Well-Being and Cognitive Function in People With Long COVID and ME/CFS, and Age-Matched Healthy Controls: A Case-Case-Control Study.
    Am J Med. 2025;138:1029-1037.
    PubMed         Abstract available


    Ann Intern Med

  5. AMAN M, Jeevananthan A, Martinez-Cruz M, Namasingh N, et al
    Endocrinology: What You May Have Missed in 2024.
    Ann Intern Med. 2025 Apr 1. doi: 10.7326/ANNALS-25-00990.
    PubMed         Abstract available

  6. HAMED HKA, Nachman A, Riopel N, Schuster M, et al
    Infectious Diseases: What You May Have Missed in 2024.
    Ann Intern Med. 2025 Apr 1. doi: 10.7326/ANNALS-25-00925.
    PubMed         Abstract available

  7. CORONADO GD, Petrik AF, Thompson JH, Leo MC, et al
    Patient Navigation to Improve Colonoscopy Completion After an Abnormal Stool Test Result : A Randomized Controlled Trial.
    Ann Intern Med. 2025 Apr 1. doi: 10.7326/ANNALS-24-01885.
    PubMed         Abstract available


    Arch Virol

  8. CHEN T, Xu W, Duan P, Jiang S, et al
    MF59-like adjuvant containing yeast-derived squalene enhances the humoral immune response to cell-derived influenza vaccine.
    Arch Virol. 2025;170:134.
    PubMed         Abstract available


    BMC Pediatr

  9. LI W, Zhu W, Tang X, Peng Z, et al
    Similarity of immune-associated markers in COVID-19 and Kawasaki disease: analyses from bioinformatics and machine learning.
    BMC Pediatr. 2025;25:400.
    PubMed         Abstract available


    J Immunol

  10. ALLEN JD, Medina JM, Thomas MH, Lynch A, et al
    H3 hemagglutinin proteins optimized for 2018 to 2022 elicit neutralizing antibodies across panels of modern influenza A(H3N2) viruses.
    J Immunol. 2025 May 21:vkaf092. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  11. NOETTGER S, Zech F, Nchioua R, Pastorio C, et al
    Role of N-linked glycosylation sites in human ACE2 in SARS-CoV-2 and hCoV-NL63 infection.
    J Virol. 2025 Mar 28:e0220224. doi: 10.1128/jvi.02202.
    PubMed         Abstract available

  12. GHIMIRE R, Shrestha R, Amaradhi R, Liu L, et al
    Toll-like receptor 7 (TLR7)-mediated antiviral response protects mice from lethal SARS-CoV-2 infection.
    J Virol. 2025 Mar 31:e0166824. doi: 10.1128/jvi.01668.
    PubMed         Abstract available

  13. XIAO X, Li S, Zheng Z, Ji Y, et al
    Targeting USP22 to promote K63-linked ubiquitination and degradation of SARS-CoV-2 nucleocapsid protein.
    J Virol. 2025 Apr 4:e0223424. doi: 10.1128/jvi.02234.
    PubMed         Abstract available

  14. ZHOU B, Gui Q, Liu C, Guo H, et al
    Structure and function of an unusual R452-dependent monoclonal antibody against SARS-CoV-2.
    J Virol. 2025 Apr 8:e0184424. doi: 10.1128/jvi.01844.
    PubMed         Abstract available

  15. KAWAKITA T, Sekiya T, Kameda Y, Nomura N, et al
    ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4(+) and CD8(+) T-cell responses and neutralizing antibody induction.
    J Virol. 2025 Apr 15:e0229024. doi: 10.1128/jvi.02290.
    PubMed         Abstract available

  16. DE AVILA AI, Soria ME, Martinez-Gonzalez B, Somovilla P, et al
    SARS-CoV-2 biological clones are genetically heterogeneous and include clade-discordant residues.
    J Virol. 2025 Apr 24:e0225024. doi: 10.1128/jvi.02250.
    PubMed         Abstract available

  17. SUN H, Yang Q, Zhang Y, Cui S, et al
    Syntaxin-6 restricts SARS-CoV-2 infection by facilitating virus trafficking to autophagosomes.
    J Virol. 2025 Apr 25:e0000225. doi: 10.1128/jvi.00002.
    PubMed         Abstract available

  18. NEGI V, Kuhn RJ
    A BSL-2 chimeric system designed to screen SARS-CoV-2 E protein ion channel inhibitors.
    J Virol. 2025 Apr 30:e0225224. doi: 10.1128/jvi.02252.
    PubMed         Abstract available

  19. ZHANG S, Xu C-L, Wang J, Xiong X, et al
    Spike proteins of coronaviruses activate mast cells for degranulation via stimulating Src/PI3K/AKT/Ca(2+) intracellular signaling cascade.
    J Virol. 2025 Apr 30:e0007825. doi: 10.1128/jvi.00078.
    PubMed         Abstract available


    PLoS One

  20. FOULKES S, Munro K, Sparkes D, Broad J, et al
    Adapting COVID-19 research infrastructure to capture influenza and respiratory syncytial virus alongside SARS-CoV-2 in UK healthcare workers winter 2022/23: Results of a pilot study in the SIREN cohort.
    PLoS One. 2025;20:e0316131.
    PubMed         Abstract available

  21. MATAS JL, Raskina K, Tong S, Forney D, et al
    Comparative analysis of influenza healthcare disparities in the United States using retrospective administrative claims from Medicaid and commercial databases, 2015-2019.
    PLoS One. 2025;20:e0321208.
    PubMed         Abstract available

  22. SKERVIN TK, Ellmers TJ, Kal EC, Young WR, et al
    Exploring the effects of wearing facemasks on stair safety characteristics in young adults.
    PLoS One. 2025;20:e0324333.
    PubMed         Abstract available

  23. PARTOUCHE N, Maumy M, Chamaraux-Tran TN, Bertrand F, et al
    Does the IL-6/KL-6 ratio distinguish different phenotypes in COVID-19 Acute Respiratory Distress Syndrome? An observational study stemmed from prospectively derived clinical, biological, and computed tomographic data.
    PLoS One. 2025;20:e0321533.
    PubMed         Abstract available

  24. OVER D, Santana E, Amaral EFL, Lakkimsetti C, et al
    A comprehensive analysis of COVID-19 vaccination behavior: The influence of religion, information sources, political leanings, and demographic factors.
    PLoS One. 2025;20:e0323815.
    PubMed         Abstract available

  25. TLHAKO N, Coetzee SK, Ajanaku OJ, Fourie E, et al
    The impact of workplace relationships on nurse-reported quality of care and patient safety in the North West Province.
    PLoS One. 2025;20:e0323620.
    PubMed         Abstract available

  26. WARD CL, Rojas Castro MY, Chakhunashvili G, Chitadze N, et al
    COVID-19 vaccine effectiveness among healthcare workers during the Omicron period in the country of Georgia, January - June 2022.
    PLoS One. 2025;20:e0311337.
    PubMed         Abstract available

  27. CARR CR, Gentile NL, Bertolli J, Szewczyk W, et al
    Comparison of long COVID, recovered COVID, and non-COVID Post-Acute Infection Syndromes over three years.
    PLoS One. 2025;20:e0323104.
    PubMed         Abstract available

  28. CHAPARRO-NARVAEZ P, Manrique Sanchez JA, Berrio-Parra L, Urrego Ricaurte DC, et al
    Accuracy of information on the underlying cause of death: An analysis in Colombia during the COVID-19 pandemic in 2021.
    PLoS One. 2025;20:e0320466.
    PubMed         Abstract available

  29. LEE Z, Tan PL, Tan-Soo JS
    Unequal gains from remote work during COVID-19 between spouses: Evidence from longitudinal data in Singapore.
    PLoS One. 2025;20:e0324113.
    PubMed         Abstract available

  30. WU H, He X, Cao Y, Gao W, et al
    Adverse events affecting recovery from seasonal influenza vaccination in the hypertensive population: A population-based pharmacovigilance analysis.
    PLoS One. 2025;20:e0310474.
    PubMed         Abstract available

  31. FENG Y, Zhou Y, Li W, Cheng Q, et al
    The relationship between family functioning and depression among adolescents in China during the normalization stage of the COVID-19 epidemic: The mediating role of resilience.
    PLoS One. 2025;20:e0322939.
    PubMed         Abstract available

  32. KARA Y, Ozkan YS, Ullah A, Hamed YS, et al
    QSPR modeling of some COVID-19 drugs using neighborhood eccentricity-based topological indices: A comparative analysis.
    PLoS One. 2025;20:e0321359.
    PubMed         Abstract available

  33. SCHRODER D, Stolting A, Mullenmeister C, Behrens GMN, et al
    Improvement in quality of life and cognitive function in Post-COVID syndrome after online occupational therapy: Results from a randomized controlled pilot study.
    PLoS One. 2025;20:e0312714.
    PubMed         Abstract available

  34. RISTYAWAN MR, Putro US, Siallagan M
    Determining resources and capabilities in complex context: A decision-making model for banks.
    PLoS One. 2025;20:e0323735.
    PubMed         Abstract available

  35. GARCIA-ESPONA I, Kanine-Ait-Zalim AA, Alarcon JA, Garcia-Espona C, et al
    Trends in orthodontic scientific contributions: An evaluation based on the American Association of Orthodontists annual sessions.
    PLoS One. 2025;20:e0324810.
    PubMed         Abstract available

  36. SANZ M, Gutierrez-Diaz I, Gonzalez H, Rodriguez-Belvis MV, et al
    Hospitalised children with COVID-19 display an aberrant intestinal microbiota and a shift in faecal compounds related with the metabolism of vitamins and lipids.
    PLoS One. 2025;20:e0323910.
    PubMed         Abstract available

  37. MARTIN MORENO V, Martinez Sanz MI, Gonzalez IS, Vazquez MR, et al
    Socio-health factors, ability to perform instrumental and basic activities of daily living, and use of assistive mobility devices during the COVID-19 pandemic: Interrelationships and impact on long-term survival.
    PLoS One. 2025;20:e0318481.
    PubMed         Abstract available

  38. JONGKEES MJ, Bogers S, de Vries RD, GeurtsvanKessel CH, et al
    Longitudinal assessment of COVID-19 vaccine immunogenicity in people with HIV stratified by CD4+ T-cell count in the Netherlands: A two-year follow-up study.
    PLoS One. 2025;20:e0323792.
    PubMed         Abstract available

  39. PARIDANS M, Dardenne N, Gillain N, Husson E, et al
    Removing barriers to COVID-19 vaccine intention in a university population: Results of a serial mediation study through the dimensions of the Health Belief Model.
    PLoS One. 2025;20:e0322881.
    PubMed         Abstract available

  40. HENDRIX N, Parikh RV, Taskier M, Walter G, et al
    Heterogeneity of diagnosis and documentation of post-COVID conditions in primary care: A machine learning analysis.
    PLoS One. 2025;20:e0324017.
    PubMed         Abstract available

  41. VIJAYAKUMAR S, Corneau E, Erqou S, Kokkirala A, et al
    Outpatient care changes and associated mortality among Veterans with heart failure during the COVID-19 pandemic.
    PLoS One. 2025;20:e0323308.
    PubMed         Abstract available

  42. DORJEE K, Sadoff RC, Mansour FR, Dorjee S, et al
    Menstrual disturbance associated with COVID-19 vaccines: A comprehensive systematic review and meta-analysis.
    PLoS One. 2025;20:e0320162.
    PubMed         Abstract available

  43. DOGBLA L, Jaber AB, Baker JS, Boudet G, et al
    Impact of COVID on the medical activity of occupational health departments.
    PLoS One. 2025;20:e0323018.
    PubMed         Abstract available

  44. BENGOLEA A, Ruiz JI, Vega CG, Manzotti M, et al
    Clinical evolution and medical resource utilization in adult patients with respiratory syncytial virus infection at a community hospital in Argentina.
    PLoS One. 2025;20:e0324735.
    PubMed         Abstract available

  45. WANDER PL, Lowy E, Korpak A, Beste LA, et al
    Association of long COVID documentation with clinical outcomes among Veterans with diabetes.
    PLoS One. 2025;20:e0324709.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  46. FAN C, Keeffe JR, Malecek KE, Cohen AA, et al
    Cross-reactive sarbecovirus antibodies induced by mosaic RBD nanoparticles.
    Proc Natl Acad Sci U S A. 2025;122:e2501637122.
    PubMed         Abstract available


    Vaccine

  47. TIAN X, Zhou Y, Deng P, Xu N, et al
    Effectiveness and safety of a novel intranasal influenza vaccine in Chinese children: A phase IV multi-Center, randomized, double-blind, placebo-controlled clinical trial.
    Vaccine. 2025;59:127268.
    PubMed         Abstract available

  48. MYBURGH L, van Loon K, Huijbers EJM, van Beijnum JR, et al
    Guided design for the development of an evolution-proof influenza vaccine.
    Vaccine. 2025;59:127281.
    PubMed         Abstract available

  49. LIAW K, Konrath KM, Trachtman AR, Tursi NJ, et al
    DNA co-delivery of seasonal H1 influenza hemagglutinin nanoparticle vaccines with chemokine adjuvant CTACK induces potent immunogenicity for heterologous protection in vivo.
    Vaccine. 2025;59:127231.
    PubMed         Abstract available

  50. SOBLE A, Malhame M, Malvolti S, Mantel C, et al
    Identification and sizing of the current use cases for seasonal influenza vaccines.
    Vaccine. 2025 May 15:127233. doi: 10.1016/j.vaccine.2025.127233.
    PubMed         Abstract available

  51. GIANNINI F, Hogan AB, Cameron E, Le H, et al
    Estimating the impact of Western Australia's first respiratory syncytial virus immunisation program for all infants: A mathematical modelling study.
    Vaccine. 2025;56:127155.
    PubMed         Abstract available

  52. MANDVIWALA AS, Munje AK, Huckriede ALW, Arankalle VA, et al
    Immunogenicity evaluation of respiratory syncytial virus prefusogenic-F based virus-like-particles consisting of G and M proteins in mice.
    Vaccine. 2025;56:127203.
    PubMed         Abstract available

  53. PADRON-REGALADO E, Escudero Gonzalez NA, Del Carmen Selvera HN
    Morbidity of viral vaccine preventable diseases in the Mexican states bordering the U.S., 2014-2023.
    Vaccine. 2025;56:127192.
    PubMed         Abstract available

  54. BOUADDI O, Khalis M, Abdellatifi M, Seedat F, et al
    Behavioural and social drivers of vaccination among child and adult migrants in Morocco: A qualitative interview study.
    Vaccine. 2025;56:127166.
    PubMed         Abstract available

  55. SEFAT KMSR, Kulkarni R, Trinh J, Leekha A, et al
    Mucosal vaccines with STING-agonist liposomal formulations inhibit RSV (respiratory syncytial virus) replication in cotton rats.
    Vaccine. 2025;56:127183.
    PubMed         Abstract available

  56. KANESHITA S, Chambers CD, Johnson D, Kavanaugh A, et al
    Short-term side effects following COVID-19 vaccination in pregnancies complicated by autoimmune inflammatory rheumatic diseases: A prospective cohort study.
    Vaccine. 2025;56:127194.
    PubMed         Abstract available

  57. MOTTA M, Callaghan T, Ross JC, Gargano L, et al
    Promoting RSV vaccine confidence through reversal narrative (RN) messaging.
    Vaccine. 2025;56:127178.
    PubMed         Abstract available

  58. PAUL MJ, Hudda MT, Pallett S, Groppelli E, et al
    Mucosal immune responses to SARS-CoV-2 infection and COVID-19 vaccination.
    Vaccine. 2025;56:127175.
    PubMed         Abstract available

  59. KISLAYA I, Caserta M, Faye SLB, Dia OK, et al
    Evaluating the effects of a multisectoral dialogue-based COVID-19 awareness-raising intervention in a limited-resource setting: A quasi-experimental study in Senegal.
    Vaccine. 2025;56:127168.
    PubMed         Abstract available

  60. SHANKER A, Vlaev I
    The social influence of the corrections of vaccine misinformation on social media.
    Vaccine. 2025;56:127177.
    PubMed         Abstract available

  61. BAYSAC DJ, Guay M, Chen R, Dube E, et al
    Did inequalities in COVID-19 vaccination resolve over time? Insights from the Canadian Community Health Survey.
    Vaccine. 2025;56:127153.
    PubMed         Abstract available

  62. HANSEN BT, Kristoffersen AB, Stecher M
    Vaccination readiness among adults in Norway: A cross-sectional survey using the 7C model.
    Vaccine. 2025;56:127169.
    PubMed         Abstract available

  63. OHNO M, Sekiya T, Obeng-Kyeremeh R, Handabile C, et al
    Optimization of the preparation method of inactivated intact virus particle vaccine for COVID-19.
    Vaccine. 2025;56:127173.
    PubMed         Abstract available

  64. LANATA CF, Ochoa TJ, Bancalari EM, Baylor NW, et al
    Testing an experimental vaccine during a public health emergency: Lessons from a Peruvian case.
    Vaccine. 2025;56:127176.
    PubMed         Abstract available

  65. MCGRATH LJ, Khan FL, Lopez SMC, Brouillette MA, et al
    2023-2024 COVID-19 vaccine uptake among immunocompromised individuals in two US states.
    Vaccine. 2025;56:127120.
    PubMed         Abstract available


    Virus Res

  66. CHEN J, Zhao S, Yan H, Huang Y, et al
    Plasma SARS-CoV-2 nucleocapsid antigen levels are associated with lung infection and tissue-damage biomarkers.
    Virus Res. 2025;356:199580.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »